DailyIQ
|
Sector:HealthcareAll sectors
Last updated 94 days ago

EXAS·EXAS

$.
+. (+.%)
After Hours
High
$103.42
Open
$103.17
Market Cap
19.70B
52W High
$103.54
Low
$103.14
P. Close
$103.23
P/E
-
52W Low
$38.81
Fwd P/E
-
Mean Target
-
Technical Score (1D)
86
BUY
News Sentiment
57
BULLISH
Exact Sciences' (EXAS) Q4 earnings are the primary focus today, with several key developments emerging. The company reported a Q4 loss per share that missed analyst estimates, though sales figures exceeded expectations. This EPS miss represents a substantial decrease compared to the prior year's losses, which could lead to volatility in the stock. Exact Sciences also announced record fourth quarter and full-year 2025 results, with significant revenue increases across both Screening and Precision Oncology segments. Total revenue reached $3.25 billion for 2025, and operating cash flow increased by 133%. However, the Q4 earnings snapshot revealed a miss on EPS, significantly underperforming estimates, though revenue saw a substantial increase compared to the prior year. Traders should assess the sustainability of revenue gains against the backdrop of ongoing operational expenses. Investors should note the earnings calendar for future releases to gauge the company's performance.
Earnings Summary
Exact Sciences Corporation, operating within the Healthcare sector and Diagnostics & Research industry, provides cancer screening and diagnostic test products. The company's offerings include Cologuard, a non-invasive test for colorectal cancer, and the Oncotype DX tests. Recent news indicates a focus on advancing screening and diagnostic products. In Q4 2024, Exact Sciences reported an EPS of -$0.06, beating the estimated -$0.1869, with revenue at $713.42 million. The company's Q4 2025 performance is not yet available, but the revenue estimate is $824.08 million. Exact Sciences beat EPS estimates in the most recent quarter, but the EPS miss represents a substantial decrease compared to the prior year's losses. The company's revenue saw a substantial increase compared to the prior year. Exact Sciences' revenue reached $3.25 billion for 2025, and operating cash flow increased by 133%. The company's Oncotype DX Breast Recurrence Score test has been used by over 2,000,000 patients, solidifying its role in breast cancer diagnostics. This milestone reinforces Exact Sciences' position in genomic diagnostics and could attract further investment. Investors should watch for further developments in the company's financial performance and analyst ratings to assess the sustainability of its recent gains. Key will be the company's ability to manage its cash burn rate and achieve profitability.

EPS

EstBeatMiss
$-0.23$-0.13$-0.03$0.07$0.17Q4'24Q4'25
QtrEstActual+/−
Q4'25$0.12 - -
Q4'24$-0.19$-0.06+67.9%

Revenue

EstBeatMiss
$697M$733M$769M$805M$841MQ4'24Q4'25
QtrEstActual+/−
Q4'25$824M - -
Q4'24 - $713M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

EXAS Stock Snapshot

EXAS is currently trading at $103.14, giving EXAS a market cap of 19.70B. Today's range spans $103.14–$103.42, with shares opening at $103.17 and moving down $0.09 (0.1%) from the prior close. DailyIQ's technical score sits at 86/100 (BUY) with a news sentiment reading of 57/100.

Over the past year EXAS has traded between $38.81 and $103.54 - the current price is +165.8% off the 52-week low and -0.4% from the high.

The breakout geometry on EXAS is constructive - price at $103.14 (near 52-week highs in $38.81–$103.54), scoring 86/100 (BUY) with neutral sentiment (57/100). At 19.70B in Healthcare market cap, technical breakouts through prior resistance at this capitalization tier tend to be better validated than in smaller-cap peers - institutional participation means that cleared levels attract follow-through buying rather than immediate fade behavior.

The combination of a BUY signal (86/100) and neutral news sentiment (57/100) puts EXAS on the screens of active managers who run quality-momentum overlays — a cohort that can build meaningful positions at 19.70B in Healthcare market cap without immediately moving the stock. At $103.14 (near 52-week highs in the $38.81–$103.54 range), the entry discipline is clean and the potential re-rating if sentiment continues to improve is meaningful.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

0+ articles
Loading latest news…